In this issue
Cholesterol-lowering statin therapy for healthy people is not as simple as 'yes' or 'no'Subscription
Recent reports of large trials extolling the virtues of statins have led many to believe that low-risk patients should take them, but an examination of the evidence provides food for thought.
Multiple myeloma: pharmacological managementSubscription
Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the last 40 years, with survival rates quadrupling. Significant advances in both treatment and supportive therapies have contributed to these improved outcomes and are discussed in this article.
In the UK, cervical cancer is the second most common cancer in women aged under 35 years. Human papillomavirus (HPV) types 16 and 18 (both high risk) are necessary precipitants in at least 70% of cervical cancers but may contribute to more than 80% of cervical cancers in Scotland. Both the prophylactic bivalent (Cervarix; GlaxoSmithKline) and quadrivalent (Gardasil; Merck) vaccines prevent infection with HPV types 16 and 18, and have been shown to induce avid and sustained neutralising ...
Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract and affects patients’ quality of life. Treatment of IBD involves induction and maintenance of remission. Current available therapies include anti-inflammatory aminosalicylates and corticosteroids, immunosuppressive agents, antibiotics and biologic agents. Some patients are not fully responsive to conventional treatment or lose efficacy over time. Recently approved ...
We continue to see media reports describing how pharmaceutical companies are cutting or altogether halting investment in neuroscience, thereby eliminating the possibility of innovative treatments for devastating brain disorders such as depression and
In September 2015, the medicines optimisation service (MOS) was set up within Weymouth and Portland, Dorset. The MOS pharmacist conducts in-depth domiciliary consultations with patients to improve adherence and prevent harm from inappropriate medicines administration or prescribing. The service targets patients aged over 75 years with polypharmacy, on admissions avoidance care plans or living in care homes.